Results 41 to 50 of about 91,870 (284)

Patients with Ankylosing Spondylitis Can Maintain Clinical and Functional Improvement after Switching from Infliximab Reference Product to Infliximab Biosimilar (REMSIMA): 12 Months Comparative Open-Label Study

Journal of Clinical Rheumatology and Immunology, 2022
Objective: Efficacy, tolerance, and safety of infliximab biosimilar are the same as infliximab reference product (RP) in the management of ankylosing spondylitis (AS) patients previously were on infliximab RP.
Abdulsatar J. Mathkhor, Ali Altaqi, Abdulnasser Abdullah, Amer Khudhairy   +3 more
doaj   +1 more source

Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis. [PDF]

, 2019
BackgroundCoronary artery aneurysms (CAA) are a serious complication of Kawasaki disease. Treatment with intravenous immunoglobulin (IVIg) within 10 days of fever onset reduces the risk of CAA from 25% to <5%.
Baker, Annette L, Burns, Jane C, Dahdah, Nagib, de Ferranti, Sarah D, Dionne, Audrey, Fournier, Anne, Friedman, Kevin G, Gauvreau, Kimberlee, Gould, Patrick, Newburger, Jane W, Son, Mary Beth, Tremoulet, Adriana H   +11 more
core  

A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn’s disease [PDF]

, 2014
Background: The faecal calprotectin (FC) test is a non-invasive marker for gastrointestinal inflammation. Aim: To determine whether higher FC levels in individuals with quiescent Crohn’s disease are associated with clinical relapse over the ensuing 12 ...
Allan J. Morris, Beltrán, Best, Boschetti, Centre for Evidence-based purchasing, Cosnes, Costa, D'Haens, D'Incà, Daniel R. Gaya, De Suray, Ferreiro, García-Sánchez, Gisbert, Gisbert, Graham D. Naismith, Guidi, Hanaway, Jack W. Winter, Joanna I. Munro, Jones, Kallel, Karen Rankin, Kennedy, Laharie, Lamb, Langhorst, Lemann, Louis, Lyn A. Smith, Manz, Mao, Molander, Naismith, Pardi, Primas, Roseth, Roseth, Roseth, Sarah J.E. Barry, Saverymuttu, Schoepfer, Schoepfer, Sipponen, Sipponen, Susan Laird, Sutherland, Tibble, Tibble, Van Rheenen, Wagner   +50 more
core   +1 more source

Associations of Rheumatoid Arthritis Disease Activity with Frailty Over Five Years of Follow‐up

Arthritis Care &Research, Accepted Article.
Objective To evaluate whether rheumatoid arthritis (RA) disease activity is associated with frailty both in cross‐section and longitudinally. Methods Participants within the Veterans Affairs Rheumatoid Arthritis registry enrolled from 2003 to 2022 were included. The exposure was RA disease activity measured by Disease Activity Score in 28‐joints (DAS28)
Courtney N. Loecker, Yangyuna Yang, Punyasha Roul, Aaron Baraff, Myra S. Schmaderer, Lani Zimmerman, Kaleb Michaud, Namrata Singh, Grant W. Cannon, Gary Kunkel, Ted R. Mikuls, Ariela R. Orkaby, Joshua F. Baker, Bryant R. England, Katherine D. Wysham   +14 more
wiley   +1 more source

Infliximab Biosimilar Utilization in a Large Pediatric Learning Health System

Children
Background/Objectives: Infliximab biosimilars entered the United States (US) market in November 2016. Uptake of infliximab biosimilars has been slow in adult studies.
Ross M. Maltz, Shehzad A. Saeed, Jeremy Adler   +2 more
doaj   +1 more source

Early Serum Infliximab Levels in Pediatric Ulcerative Colitis

Frontiers in Pediatrics, 2021
Background: Data on serum infliximab concentrations during induction in pediatric ulcerative colitis are limited. The study aim is to evaluate the relationship between serum infliximab concentrations during induction and short-term clinical remission in ...
Jennifer C. C. deBruyn, Jennifer C. C. deBruyn, Kevan Jacobson, Wael El-Matary, Eytan Wine, Matthew W. Carroll, Caitlin Goedhart, Caitlin Goedhart, Remo Panaccione, Iwona T. Wrobel, Hien Q. Huynh   +10 more
doaj   +1 more source

Persistencia de medicamentos biológicos durante ocho años en pacientes con artritis reumatoide y espondiloartritis [PDF]

, 2019
Objective: To calculate the persistence, over a period of eight years, the retention rate of first and second-line of treatment with biological agents in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis and to compare ...
Balsa, Alejandro, González-Fernández, María, Herrero, Alicia, Jiménez-Nácher, Inmaculada, Moreno, Francisco, Villamañán, Elena   +5 more
core   +3 more sources

Sphingomonas paucimobilis‐Driven Epithelial–Endothelial Transition in Adenomyosis Pathogenesis

Advanced Science, EarlyView.
This study identifies epithelial–endothelial transition (EET) as a novel adenomyosis pathogenic mechanism driven by Sphingomonas paucimobilis colonization. Systematic inhibitor experiments validate a TNFα→NF‐κB→MMP signaling cascade essential for EET. Critically, bacterial culture supernatant fails to induce pathological changes, demonstrating viable ...
Peigen Chen, Hao Shi, Junxian He, Ziyu Liu, Yuanyuan Zhu, Xiaoyan Liang, Guihua Liu, Xing Yang   +7 more
wiley   +1 more source

Evaluation of Infliximab Effects on Gastrointestinal Bleeding in Crohn’s Disease Using Double-Balloon Endoscopy

Case Reports in Gastroenterology, 2009
Tumor necrosis factor α plays an important role in the pathogenesis of Crohn’s disease (CD). The effects of infliximab on gastrointestinal bleeding in CD have not yet been fully evaluated.
Manzurul Chowdhury, Norihiko Kudara, Toshimi Chiba, Masaki Endo, Risaburo Akasaka, Kazumitsu Tomita, Saori Fujiwara, Tomomi Mizutani, Tamotsu Sugai, Yasuhiro Takikawa, Kazuyuki Suzuki   +10 more
doaj   +1 more source

Immunogenicity of the biosimilar CT-P13 infliximab or the original infliximab in Iraqi patients with Ankylosing spondylitis does not correlate with their demographic characteristics

مجلة كلية الطب, 2023
Background: Ankylosing spondylitis is a rare disease affecting people with hereditary factors. Its treatment includes life style modification and use of drugs such as the biologic agent infliximab or its biosimilar, CT-P13 infliximab.
Mohammed M. Kamil, Mohammed Abdul- Hassan Jabarah, Nizar A.l. Jasim   +2 more
doaj   +1 more source